1. Introduction

Medical applications distributed through digital marketplaces can influence diagnosis, treatment, medication use, mental health, reproductive decisions, and emergency care. Consequently, the vetting of medical apps raises an important legal question: To what extent should an app store be responsible for verifying the safety, accuracy, legality, and reliability of medical applications before allowing them to be downloaded?

An app store, such as the Apple App Store or Google Play Store, generally operates as a platform for distributing third-party software. Depending on the jurisdiction and the facts, it may face legal scrutiny when it distributes misleading, unsafe, unauthorised, or fraudulent medical applications.

However, an app store is not automatically liable for every injury caused by an app it distributes. Liability depends on the applicable regulatory framework, the platform's actual role, its knowledge of the risk, the representations it makes, the precautions reasonably expected of it, and the causal connection between its conduct and the harm.

The legal framework draws on medical-device regulation, consumer protection, negligence, product liability, intermediary liability, data protection, and constitutional or human-rights principles.

2. Meaning and scope of medical app vetting

Medical app vetting is the process of evaluating an application before and, where appropriate, after publication to determine whether it is safe, lawful, transparent, and fit for its stated purpose.

Regulatory verification

Determine whether the app qualifies as medical-device software and whether the necessary authorisation, registration, or conformity assessment applies.

Clinical safety and accuracy

Evaluate claims concerning diagnosis, treatment, dosage, symptom assessment, risk prediction, and medical-device performance.

Transparency and advertising

Detect unsupported claims, fake clinical endorsements, deceptive testimonials, and misleading statements about medical effectiveness.

Privacy and cybersecurity

Assess disclosures about sensitive health data, permissions, data sharing, security practices, and consent.

Post-publication monitoring

Respond to credible complaints, regulator notices, safety incidents, software updates, and evidence of newly discovered hazards.

The appropriate depth of review depends on the app's risk. A general wellness journal does not necessarily require the same scrutiny as an app claiming to diagnose a heart attack or calculate insulin doses.

3. Legal duties of app stores

A. Duty to screen regulated medical applications

The first responsibility is to identify applications that may legally qualify as medical devices. Classification should depend on what the software actually does, rather than its category, title, or disclaimer.

For example:

A medication reminder may be a relatively low-risk health application.

An application that analyses ECG signals to detect arrhythmias may qualify as medical-device software.

Software that controls an insulin pump can present significant patient-safety risks.

An app claiming to diagnose cancer requires substantially greater scrutiny than a general health-information application.

In the United States, the Food and Drug Administration (FDA) adopts a risk-based approach under the Federal Food, Drug, and Cosmetic Act. Its guidance distinguishes software that is not a medical device, software subject to limited enforcement oversight, and software functions that warrant regulatory oversight. Importantly, the FDA states that entities exclusively distributing mobile apps through app stores are not medical-device manufacturers merely because they distribute those apps.

FDA

+1

That distinction is central: the developer or manufacturer generally bears the primary medical-device compliance obligations, while the platform may have separate responsibilities under other laws.

B. Verification of regulatory authorisation

Where applicable, vetting should include checks for:

The identity of the developer and the entity responsible for the medical software.

The app's intended medical purpose and claimed functions.

Relevant registration, licensing, clearance, approval, or conformity-assessment documentation.

The validity and scope of any authorisation.

Material changes to the app that could affect its safety or regulatory status.

A platform should not treat an ordinary developer declaration as conclusive evidence that a high-risk medical application is lawful.

Apple has introduced a regulated-medical-device declaration process for qualifying apps distributed in the United States, United Kingdom, and European Economic Area. Its requirements include regulatory information for apps identified as regulated medical devices.

Apple Developer

+1

C. Clinical claims and misleading representations

App stores should distinguish between hosting a developer's claims and actively endorsing those claims.

Consider an app advertised as providing “100% accurate cancer detection using your smartphone camera.” Appropriate safeguards may include:

Requiring evidence for clinical-performance claims.

Rejecting deceptive descriptions and fabricated medical endorsements.

Requiring clear disclosure of limitations and intended users.

Preventing misleading representations about regulatory approval.

Reviewing credible reports that the app provides unsafe recommendations.

The applicable legal standard depends on the platform's role and governing law. A general marketplace is not necessarily required to independently reproduce every clinical trial. However, knowingly promoting a fraudulent or dangerous medical product can present different legal risks from passively hosting a third-party listing.

D. Privacy and cybersecurity

Medical applications may collect particularly sensitive information, including symptoms, diagnoses, fertility information, mental-health records, genetic information, and biometric measurements.

A reasonable vetting framework should assess whether the app:

Explains what information it collects and why.

Obtains legally required consent.

Uses proportionate security measures.

Avoids undisclosed sharing or deceptive secondary uses.

Provides accurate information about deletion and retention.

Complies with applicable health-data and consumer-protection laws.

Apple's App Review Guidelines impose additional restrictions on the use and disclosure of health and medical data, including restrictions on advertising-related use and inaccurate medical data written to health-management systems.

Apple Developer

E. Post-publication monitoring and removal

Vetting cannot end when an app is approved for publication. A medical app may become dangerous following an update, a cybersecurity incident, a change in its algorithm, or the discovery of previously unknown clinical limitations.

A defensible monitoring system should provide for:

A channel for patients, clinicians, and regulators to report harm.

Escalation procedures for credible and urgent safety complaints.

Reassessment when the developer changes the app's intended use.

Temporary suspension or removal where warranted.

Preservation of relevant records and cooperation with lawful regulatory requests.

The legal question is not whether a platform can guarantee that no unsafe app will ever be published. It is whether the platform has complied with the obligations applicable to its particular role and responded reasonably when material risks become apparent.

4. Important case laws and their relevance

A crucial qualification: there is no need to assume that a reported case directly establishes a universal duty for app stores to clinically validate every medical app. The following cases establish principles concerning intermediaries, product liability, consumer protection, and platform responsibility. Their application to medical app vetting is often analogical rather than a direct ruling on medical app stores.

Case 1: Shreya Singhal v. Union of India, (2015) 5 SCC 1

Court: Supreme Court of India.

Legal issue: Intermediary liability and restrictions on online speech.

Principle: The Supreme Court invalidated section 66A of the Information Technology Act, 2000, and read down section 79's intermediary-liability framework. For section 79, the judgment distinguished legally recognised forms of intermediary knowledge from a general obligation to act on every private allegation.

Relevance to medical app stores: The decision helps explain why platforms cannot automatically be treated as the authors of everything third parties publish. However, it does not create immunity from every other legal obligation.

An app store facing a complaint about a dangerous diagnostic application must be assessed under the applicable intermediary rules, regulatory requirements, consumer-protection law, and any independent obligations arising from its own conduct.

Limit: This judgment does not establish a specific clinical-testing duty for medical app stores.

Case 2: Christian Louboutin SAS v. Nakul Bajaj, 2018 SCC OnLine Del 12215

Court: Delhi High Court.

Legal issue: Whether an online marketplace's own conduct affects its claim to intermediary protection.

Principle: The Delhi High Court examined the extent of an e-commerce platform's participation in commercial transactions and the significance of its active role when intermediary protection is claimed.

Relevance to medical app stores: The decision supports a fact-sensitive examination of a platform's actual activities. A marketplace that merely facilitates distribution may stand differently from one that actively curates, markets, modifies, or makes substantive representations about a medical product.

For example, an app store's conduct could warrant closer scrutiny if it prominently represents a particular diagnostic app as clinically validated without an adequate basis.

Limit: The case concerned online commerce and trademarks, not the clinical safety of software. It does not independently establish that active participation makes an app store liable for every injury.

Case 3: Parker v. Google, Inc., 242 F. App'x 833 (3d Cir. 2007)

Court: United States Court of Appeals for the Third Circuit.

Legal issue: Liability of an online intermediary for third-party content.

Principle: The court affirmed dismissal of claims against Google arising from third-party material and considered the protection afforded by section 230 of the Communications Decency Act.

Relevance to medical app vetting: The case illustrates that an intermediary is not necessarily responsible for third-party content merely because its services make that content accessible.

However, an app store's potential liability for its own commercial representations, independent conduct, or duties imposed by other legislation must be analysed separately.

Limit: Section 230 does not provide a blanket answer to product-liability or medical-device questions, and its application depends on the nature of the claim and the jurisdiction.

Case 4: Coronavirus Reporter v. Apple, Inc., No. 1:21-cv-00047

Court: U.S. District Court for the District of New Hampshire, 2021.

Legal issue: App Store rejection of an application that collected COVID-19-related information.

The developer alleged that Apple rejected its application under requirements concerning the credentials of developers of COVID-related apps and the verification of user-generated data. The case addressed claims arising from Apple's decision not to distribute the application.

Relevance: This is particularly relevant because it concerns a health-related app and the platform's exercise of gatekeeping powers. It demonstrates that medical-app review policies can generate legal disputes involving contracts, representations, and platform discretion.

The case should not be treated as establishing that app stores must approve every medically useful application or independently validate all clinical data.

Document 33 (D.N.H. 2021) :: Justia

+1

Case 5: Epic Games, Inc. v. Apple Inc., 67 F.4th 946 (9th Cir. 2023)

Court: U.S. Court of Appeals for the Ninth Circuit.

Legal issue: App distribution restrictions, competition, and Apple's control over its application ecosystem.

Principle and relevance: The litigation examined Apple's control over app distribution, review procedures, and commercial terms. It illustrates that an app store's role may extend beyond passive hosting to significant control over the software-distribution environment.

For medical apps, such control can strengthen the practical importance of fair, consistent, and transparent review policies. It may also raise competition concerns if access rules are discriminatory or applied in ways that violate applicable antitrust law.

Limit: The case did not establish a general medical-device verification duty or decide liability for patient injury caused by an unsafe medical application.

Justia Law

5. Statutory framework in India

For Indian users and developers, app-store responsibility must be assessed through several overlapping laws.

Indian law does not automatically impose every developer's medical-device obligation on the app store. The precise duties depend on whether the platform merely distributes software or also performs functions that make it a manufacturer, seller, service provider, advertiser, or other regulated participant.

The legal classification of health software and the associated civil-liability framework are discussed in the India digital-health legal guide published by CMS.

CMS Law

+1

Important Indian principles

1. Consumer protection: If a platform itself makes deceptive medical claims or undertakes responsibilities that it fails to fulfil, consumer-protection questions may arise. Whether a particular product-liability provision applies to the platform depends on its statutory classification and conduct.

2. Intermediary protection: Section 79 is conditional, not absolute immunity. The principles in Shreya Singhal must be read in the context of the statutory requirements and the distinction between third-party information and the platform's own conduct.

3. Privacy: A platform that processes health-related personal data must assess its obligations under the applicable data-protection regime. The obligations of an app developer and an app marketplace may differ.

4. Medical-device regulation: Regulatory compliance primarily follows the product's intended purpose, functionality, and applicable classification. An app store should not assume that every health or wellness app is a regulated medical device, nor that every app labelled “wellness” is exempt.

6. Comparative position: United States, European Union, and India

United States

The FDA regulates qualifying medical-device software, while its mobile medical app policy does not treat entities exclusively distributing apps as medical-device manufacturers solely because of their distribution role. The FTC and other laws may impose separate obligations relating to deceptive claims and consumer health information.

FDA

+1

European Union

The Medical Device Regulation (EU) 2017/745 can apply to software intended for medical purposes. The Digital Services Act may impose separate platform obligations, depending on the service and applicable provisions. These regimes should not be confused: medical-device conformity and platform due diligence are distinct legal questions.

India

Medical software may be regulated under the Drugs and Cosmetics Act and Medical Devices Rules. Consumer-protection, privacy, intermediary, and telemedicine rules may also apply, but the precise obligations depend on the functions performed by each participant.

CMS Law

+1

7. When can an app store be liable for harm?

Consider a hypothetical situation in which a medical app incorrectly identifies a dangerous cardiac rhythm as normal, causing a patient to delay emergency treatment.

The potential liability analysis would examine the following:

Developer or manufacturer: Was the software defectively designed, inadequately tested, misleadingly marketed, or accompanied by insufficient warnings?

App store: Did it breach a specific legal or contractual obligation? Did it make its own misleading representations? Did it ignore a credible safety notice where the applicable law required action?

Healthcare professional: Did a clinician use the app reasonably, or rely on its output contrary to accepted medical practice?

Causation: Did the software error or the platform's actionable conduct cause or materially contribute to the injury?

Defences and remedies: What statutory protections, contractual terms, causation requirements, and remedies apply in the relevant jurisdiction?

A patient cannot establish platform liability merely by showing that the app was downloaded from the platform. Conversely, a platform cannot necessarily defeat a claim simply by describing itself as a neutral intermediary if the claim concerns its own conduct or an independent legal duty.

8. Recommended legal framework for medical app vetting

A proportionate vetting system should use a risk-based approach.

These are illustrative categories, not official statutory classifications. The applicable medical-device classification must be determined under the relevant jurisdiction's rules.

Platforms should also document the basis for approval or rejection, provide developers with a fair correction process where appropriate, and avoid implying that app-store approval is equivalent to independent clinical certification.

9. Conclusion

App store responsibility for medical app vetting rests on a balance between public health, innovation, consumer protection, and the legal distinction between software developers and distribution platforms.

The strongest legal approach is not to impose automatic liability for every medical error. Instead, it is to require appropriate regulatory checks, truthful representations, proportionate safety review, protection of health data, and effective responses to credible evidence of harm where the law requires them.

The cases Shreya Singhal, Christian Louboutin, Parker, Coronavirus Reporter, and Epic Games help explain intermediary protection, platform conduct, and distribution control. They do not collectively establish a universal obligation for app stores to conduct independent clinical trials. Their value lies in clarifying the legal principles from which more specific duties may arise.

Central proposition: An app store's responsibility should increase with its actual role, its own representations, the foreseeable severity of the medical risk, and any specific legal obligations it has undertaken or is required to fulfil.

Research note: This is a comparative legal explanation for academic study, not a jurisdiction-specific legal opinion. For litigation or regulatory compliance, the current statutory text, relevant implementing rules, and binding judgments should be checked for the particular country and type of medical application.